Determinants of psychosis vulnerability; focus on MEF2- and glucocorticoid signaling

Leiden Repository

Determinants of psychosis vulnerability; focus on MEF2- and glucocorticoid signaling

Title: Determinants of psychosis vulnerability; focus on MEF2- and glucocorticoid signaling
Author: Speksnijder, Niels
Publisher: Division of Medical Pharmacolgy, Leiden Academic Center for Drug Research (LACDR), Faculty of Medicine / Leiden University Medical Center (LUMC), Leiden University
Issue Date: 2013-11-28
Keywords: Myocyte enhancer factor 2
Glucocorticoid receptor
Schizophrenia
Psychosis
Hippocampus
CA1
Roscovitine
Amphetamine
Abstract: Schizophrenia is heritable, but even in monozygotic twins differences in susceptibly exists. What is causing this difference in genetically identical individuals? The objective of this thesis was to identify novel susceptibility genes and pathways for psychosis in a psychostimulant mouse model which is considered a model for psychosis. Genome-wide analysis of transcripts in the hippocampal CA1, driving mesocortical dopaminergic activity, which has a prominent role in schizophrenia, revealed differential expression of target genes of Myocyte Enhancer Factor 2 (MEF2) and Glucocorticoid Receptor (GR). This suggest that this gene network is involved in sensitivity to amphetamine. In primary hippocampal neurons, knockdown of MEF2 reduced the expression of c-Jun and abolished its regulation by GR. Moreover, activation of MEF2 by neuronal depolarization was attenuated by glucocorticoids, suggesting a mutual feedback regulation of these transcription factors. Finally, in vivo MEF2 and GR appeared to be active in the induction phase of amphetamine sensitization. Overall, the findings suggest that in the hippocampus activation of GR can modulate the role of MEF2 target genes in induction of behavioral sensitization. This finding points to the hippocampus as an exciting target for further studies on the role of MEF2 and GR in the precipitation of psychosis susceptibility.
Description: Promotor: E.R. de Kloet, Co-promotor: N.A. Datson
With summary in Dutch
Faculty: LUMC
Citation: Speksnijder,N., 2013, Doctoral thesis, Leiden University
ISBN: 9789053357613
Sponsor: This research was financially supported by Top Institute Pharma project nr # T5-209. Additional support was received from the Royal Netherlands Academy of Arts and Sciences (KNAW), the International Research Training Group funded by NWO (DN95-420) and MEERVOUD (836.06.010) funded by NWO. Printing of this dissertation was kindly supported by TI Pharma.
Handle: http://hdl.handle.net/1887/22544
 

Files in this item

Description Size View
application/pdf Full text 5.082Mb View/Open
application/pdf Cover 921.5Kb View/Open
application/pdf Title page_Table of contents_Preface 188.0Kb View/Open
application/pdf Chapter 1 General introduction 904.1Kb View/Open
application/pdf Chapter 2 1.307Mb View/Open Full text at publisher site
application/pdf Chapter 3 1.947Mb View/Open Full text at publisher site
application/pdf Chapter 4 661.0Kb View/Open
application/pdf Chapter 5 484.9Kb View/Open
application/pdf Chapter 6 General discussion 607.7Kb View/Open
application/pdf Addendum summary 163.4Kb View/Open
application/pdf Addendum Summary in Dutch 163.7Kb View/Open
application/pdf Addendum acknowledgements 135.5Kb View/Open
application/pdf Addendum Curriculum Vitae_List of publications 132.9Kb View/Open
application/pdf Propositions 118.6Kb View/Open

This item appears in the following Collection(s)